Novo Nordisk's Stock Is Down 40% — but Pipeline Wins and a China Bet Are Rewriting the Script

Despite a 40% stock drop and a major cyber breach, Novo Nordisk advances with Wegovy approvals, China investment, and an analyst upgrade.

The headline numbers for Novo Nordisk tell a grim story. At around €38 a share, the stock has shed more than 40% over the past twelve months and sits a staggering 41% below its 52-week high of €65.20. Yet beneath the surface, a different narrative is taking shape—one of regulatory breakthroughs, geographic expansion, and a pipeline that refuses to be overshadowed by a costly cyber incident.

That incident is the elephant in the room. In mid-June 2026, the company confirmed that the extortion group FulcrumSec had breached internal IT systems, allegedly stealing over 1.3 terabytes of data—more than 700,000 files. The haul includes research data, clinical trial documents, employee and patient information, and proprietary AI models. The initial intrusion is believed to have occurred as early as March 2026. Novo Nordisk refused a $25 million ransom demand, and FulcrumSec now plans to sell the data privately. While the company says core operations have remained unaffected, the exposure of sensitive R&D and clinical data represents a material uncertainty that analysts and investors are only beginning to price in.

But while cybersecurity dominates the short-term worry list, Novo Nordisk is quietly building bridges to the future in China. The company is funnelling 200 million yuan (roughly $29 million) into its production site in Tianjin, expanding lines for finished drugs and injection pens. That brings total investment in China to over 17 billion yuan since 2003. CEO Mike Doustdar also confirmed that the company will soon seek Chinese regulatory approval for the oral version of Wegovy, already greenlit in the UK. A pill formulation could dramatically widen access in a market where injection aversion is common and local competitors are closing fast.

The flagship Wegovy franchise, meanwhile, is evolving beyond weight loss. In early April 2026, the UK’s National Institute for Health and Care Excellence (NICE) recommended the drug to prevent heart attacks and strokes in overweight adults with established cardiovascular disease—backed by a trial showing a 20% reduction in major adverse cardiac events. This positions Wegovy as a cardiology drug, not just an anti-obesity therapy, and unlocks health-system budgets that pure weight-management indications rarely reach. The US Food and Drug Administration had already approved a higher 7.2 mg dose in March 2026, which delivered an average 20.7% weight loss over 72 weeks.

Berenberg took note. On 18 June 2026, the broker lifted its price target for Novo Nordisk to 325 Danish kroner from 300, maintaining a buy recommendation. The rationale: a deepening pipeline and novel delivery formats should cushion the impact of patent expirations in the medium term.

Technically, the stock has at least stabilised. At €38.02 (or €38.20 in the latest quote), it sits roughly 4% above its 50-day moving average and has recovered nearly 26% from the March trough of €30.25. Regaining the 200-day average of €41.29 would mark a further milestone, but the tape suggests the worst of the selling is over.

The competitive landscape remains fierce. Eli Lilly won FDA approval in April 2026 for its obesity drug Foundayo, adding pressure to the GLP-1 market. Novo Nordisk’s high-dose Wegovy and its new cardiovascular indication give it strong cards, but no guarantees. A subscription model introduced for self-pay patients—saving up to $1,200 a year—along with a €432 million investment in its Irish plant for oral GLP-1 production underscore a volume-over-price strategy to lock in market share.

With a market capitalisation of roughly €168 billion, the valuation does not yet fully reflect the long-term earnings potential from these pipeline and geographic moves. The cyberattack is a genuine headwind that demands scrutiny. But those who keep one eye on the data breach and the other on the regulatory and commercial advances may find a pharma group that, despite its recent share price, is moving forward on multiple fronts.